Opus Genetics, Inc.
Opus Genetics, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Next quarterly earnings (projected) on October 31, 2026, a projected date rather than a confirmed one. There are 5 upcoming events on record.
Cash runway is approximately 20.9 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Across 13 concluded trials, 100% reached completion rather than being terminated or withdrawn.
| Date | Event | Type | Phase |
|---|---|---|---|
| October 31, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| August 15, 2027 | OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity | Trial Milestone | Phase 3 |
| June 15, 2028 | Safety and Tolerability Subretinal OPGx-001 for LCA5-Associated Inherited Retinal Degeneration (LCA5-IRD) and Non-interventional Arm With Untreated Patients | Trial Milestone | Phase 1/Phase 2 |
| August 15, 2030 | Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB) | Trial Milestone | Phase 1/Phase 2 |
| December 15, 2032 | Safety and Tolerability of Subretinal OPGx-RDH12-1001 for LCA-Associated Inherited Retinal Degeneration (LCA-IRD) | Trial Milestone | Phase 1/Phase 2 |
Track IRD alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open IRD in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.